![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » STUDY: CELECOXIB MAY INCREASE BENEFIT OF ERLOTINIB IN LUNG CANCER
STUDY: CELECOXIB MAY INCREASE BENEFIT OF ERLOTINIB IN LUNG CANCER
June 2, 2006
The addition of celecoxib (Celebrex) to treatment with erlotinib (Tarceva) for advanced non-small cell lung cancer (NSCLC) appears to be safe and to increase the proportion of patients who respond to erlotinib, suggest the results of a Phase I trial.
Previous research has demonstrated that the cyclooxygenase 2 (COX-2) and epidermal growth factor receptor tyrosine kinase (EGFR-TK) are overexpressed in some cancers, including NSCLC. Erlotinib is a highly specific EGFR-TK inhibitor, and celecoxib is a COX-2 inhibitor.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct